Abstract
Background: Ductal carcinoma of the pancreas is unresectable for cure in the majority of patients. We reviewed our results and cost effectiveness of surgical and endoscopic biliary bypass for unresectable pancreatic cancer to evaluate the comparable outcomes.
Methods: Between 1990 and 1992, 136 patients were managed operatively or endoscopically for pancreatic carcinoma. Excluding potentially curative resections and patients without follow-up, 34 patients endoscopically stented and 32 patients surgically bypassed were evaluated.
Results: Mean patient age was older (72.1 vs. 69.3 years) but average performance status was comparable (0.8 vs. 0.9 Eastern Cooperative Oncology Group grading) in the medical treatment group. The initial hospital stay was significantly longer for surgical patients (mean 14 vs. 7 days, p<0.001), with higher average charges ($18,325 vs. $9,663). Twelve stented patients required rehospitalization (average charge of $4,029), and eight surgical patients were readmitted (average charge of $6,776). An average of 1.7 stent changes (average charge $1,190) were required. Mean survival was longer for the stented group (9.7 vs. 7.3 months, p=0.13).
Conclusions: Endoscopic stenting for unresectable pancreatic cancer provides equivalent duration of survival at reduced cost and shorter hospital stay, although subsequent stent changes are necessary. When curative resection is not possible, endoscopic biliary drainage should be considered a good first choice for palliative management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Trede M. Treatment of pancreatic carcinoma: the surgeon's dilemma.Br J Surg 1987;74:79–80.
Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994.CA 1994;44:7–26.
Singh SM, Longmire WP, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience.Ann Surg 1990;212:132–9.
Pedrazzoli S, Bonadimani B, Sperti C, et al. Evaluation of surgical risk in palliation and resection of pancreatic cancer.Int J Pancreatol 1992;12:219–26.
van den Bosch RP, van der Schelling GP, Klinkenbijl JHG, Mulder PGH, van Blankenstein M, Jeekel J. Guidelines for the application of surgery and endoprosthesis in the palliation of obstructive jaundice in advanced cancer of the pancreas.Ann Surg 1994;219:18–24.
Hatfield ARW. Palliation of malignant obstructive jaundice—surgery or stent?Gut 1990;31:1339–40.
Sarr MG, Cameron JL. Surgical palliation of unresectable carcinoma of the pancreas.World J Surg 1984;8:906–18.
Huguier M, Baumel H, Manderscheid JC, Houry S, Fabre JM. Surgical palliation for unresected cancer of the exocrine pancreas.Eur J Surg Oncol 1993;19:342–7.
Pretre R, Hauber O, Robert J, Sorabia C, Egeli RA, Rohner A. Results of surgical palliation for cancer of the head of the pancreas in periampullary region.Br J Surg 1992;79:795–8.
Andersen JR, Sorensen SM, Kruse A, Rokkjaer M, Matzen P. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.Gut 1989;30:1132–5.
Smith AC, Dowsett JS, Hattfield ARW, et al. Prospective randomized trial of bypass surgery versus endoscopic stenting in patients with malignant obstructive jaundice [Abstract].Gut 1989;30:1513.
Sheperd HA, Royle G, Ross APR, Diba A, Arthur M, Colin-Jones D. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial.Br J Surg 1988;75:1166–8.
Sonnenfeld T, Gabrielsson N, Granqbist S, Perbeck L. Nonresectable malignant bile duct obstruction. Surgical bypass or endoprosthesis.Acta Chir Scand 1986;152:297–300.
Hyoty MK, Nordvack IH. Biliary stent or surgical bypass in unresectable pancreatic cancer with obstructive jaundice.Acta Chir Scand 1990;156:391–6.
Frakes JT, Johanson JF, Stake JJ. Optimal timing for stent replacement in malignant biliary tract obstruction.Gastrointest Endosc 1993;39:164–7.
Purposes and principles of staging. In: Beahrs OH, Henson DE, Hutter RVP, Meyers MH, eds.Manual for staging of cancer. 3rd ed. Philadelphia, PA: J.B. Lippincott Co.; 1988:3–10.
Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades.Br J Surg 1992;79:8–20.
Potts JR, Broughan TA, Hermann RE. Palliative operations for pancreatic carcinoma.Am J Surg 1990;159:72–8.
Sgehendra N, Reijnders-Frederix V. Palliative bile duct drainage: a new endoscopic method introducing a transpapillary drain.Endoscopy 1980;12:8–11.
Earnshaw JJ, Hayter JT, Teastale C, Beckly DE. Should endoscopic stenting be the initial treatment of malignant biliary obstruction?Ann R Coll Surg Engl 1992;74:338–41.
Huibregtse K. Biliary stenting: cosmetic or clinical value?Scand J Gastroenterol 1992;27(suppl 192):77–9.
Glattli A, Stain SC, Baer HU, Schweizer W, Triller J, Blumgart LH. Unresectable malignant biliary obstruction: treatment by self-expandable biliary endoprosthesis.HTB Surg 1993;6:175–84.
Mouiel J, Katkhouda N, White S, Dumas R. Endolaparoscopic palliation of pancreatic cancer. Brief clinical report.Surg Laparosc Endosc 1992;2:241–3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raikar, G.V., Melin, M.M., Ress, A. et al. Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer. Annals of Surgical Oncology 3, 470–475 (1996). https://doi.org/10.1007/BF02305765
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02305765